🇺🇸 FDA
Pipeline program

teclistamab, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, teclistamab, Privigen 100 mg/ml solution for infusion

64007957MMY1001

Phase 2 small_molecule active

Quick answer

teclistamab, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, teclistamab, Privigen 100 mg/ml solution for infusion for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials